| 原发性胆汁性胆管炎的药物治疗进展 |
| |
| 引用本文： | 郝娟,吕靖,邢枫,杨全军,刘成海.原发性胆汁性胆管炎的药物治疗进展[J].临床肝胆病杂志,2020,36(1):222-226. |
| |
| 作者姓名： | 郝娟 吕靖 邢枫 杨全军 刘成海 |
| |
| 作者单位： | 上海中医药大学附属上海市中西医结合医院,上海200082;上海中医药大学附属曙光医院肝病研究所,上海201203;上海交通大学附属第六人民医院药剂科,上海200233;上海市中医临床重点实验室,上海201203 |
| |
| 基金项目： | 国家自然科学基金资助项目(81803874) |
| |
| 摘 要： | 原发性胆汁性胆管炎是一种病因及发病机制尚不明确的胆汁淤积性肝病。熊去氧胆酸和奥贝胆酸是美国食品药品监督管理局批准使用的治疗药物,两者均有减轻肝内胆汁淤积的作用,但仍有部分患者对其治疗无生化应答,亟需探索新的治疗药物或方法。贝特类药物、免疫抑制剂及中医药对原发性胆汁性胆管炎患者有一定疗效,但临床安全性及作用机制尚需进一步研究。
|
| 关 键 词： | 肝硬化 胆汁性 药物疗法 中西医结合疗法 |
Advances in drug therapy for primary biliary cholangitis |
| |
| Institution: | (Shanghai Integrated Traditional Chinese and Western Medical Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200082,China) |
| |
| Abstract: | Primary biliary cholangitis(PBC) is a cholestatic liver disease with unclear etiology and pathogenesis. Ursodeoxycholic acid and obeticholic acid are the therapeutic drugs for PBC approved by the US Food and Drug Administration,both of which have the effect of alleviating intrahepatic cholestasis. However,some patients still have poor biochemical response to them,and it is urgent to explore new therapeutic drugs or methods. Fibrates,immunosuppressants,and traditional Chinese medicine have a certain effect in the treatment of patients with PBC,but further studies are needed to analyze their clinical safety and mechanism of action. |
| |
| Keywords: | liver cirrhosis biliary drug therapy TCM WM therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
